First-line chemotherapy for mCRC—a review and evidence-based algorithm. (Q38555200)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

review article

1 reference

title

First-line chemotherapy for mCRC—a review and evidence-based algorithm (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Marta Schirripa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Lisa Salvatore

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Alfredo Falcone

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Fotios Loupakis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Carlotta Antoniotti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Roberto Moretto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Gianluca Masi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

28 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

607-619

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26215044%20AND%20SRC:MED&resulttype=core&format=json

Colorectal cancer statistics, 2014.

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Platinum-sensitivity in metastatic colorectal cancer: towards a definition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2015.129